| Q33378464 | Alemtuzumab in clinical practice: a British Columbia experience |
| Q36768605 | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use |
| Q34549313 | Allogeneic transplantation for chronic lymphocytic leukemia |
| Q42434778 | Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia |
| Q38355000 | CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells |
| Q58001012 | Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis |
| Q36913228 | Chronic lymphocytic leukemia: biology and current treatment |
| Q36981738 | Emerging therapy for chronic lymphocytic leukaemia |
| Q36985872 | Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia |
| Q37119402 | Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning |
| Q37643423 | From pathogenesis to treatment of chronic lymphocytic leukaemia |
| Q80866767 | Genetically identical twin transplantation for chronic lymphocytic leukemia |
| Q37012037 | Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease |
| Q36654926 | Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. |
| Q53453511 | Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. |
| Q46061825 | Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia |
| Q34769213 | Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? |
| Q33942272 | MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. |
| Q37844139 | Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly |
| Q35563832 | Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure |
| Q33394927 | Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome |
| Q37412148 | Personalized medicine in CLL: current status and future perspectives |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
| Q39676539 | Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients. |
| Q46077879 | Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. |
| Q38108320 | Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status |
| Q37141887 | Risk categories and refractory CLL in the era of chemoimmunotherapy |
| Q37802100 | Standard of care and novel treatments for chronic lymphocytic leukemia |
| Q37275725 | Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B |
| Q36952609 | Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence? |
| Q87420514 | TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia |
| Q58276318 | Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome |
| Q36739807 | The evolving role of lenalidomide in the treatment of hematologic malignancies |
| Q36962654 | The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia |
| Q33931707 | Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells |
| Q43624295 | Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters |
| Q87806031 | Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation |
| Q34011555 | Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia |
| Q36634599 | Update on risk-stratified management for chronic lymphocytic leukemia |
| Q64904346 | Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. |
| Q39038037 | Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. |